Patent 8,206,737 US Drug Patent: Scope, Claims, and Landscape Analysis
What Does Patent 8,206,737 Cover?
United States Patent 8,206,737 was granted on June 26, 2012, to Novartis AG. It claims a pharmaceutical composition comprising a benzodiazepine derivative suitable for treatment, such as for anxiety or insomnia, with specific dosage forms and methods of use.
Key features:
- Focuses on a particular class of benzodiazepine compounds.
- Claims extend to methods of treating anxiety or insomnia.
- Encompasses pharmaceutical compositions with specified dosages (e.g., controlled release formulations).
- Covers manufacturing processes for such compounds.
What are the Specific Claims of Patent 8,206,737?
The patent includes 14 claims, predominantly directed at:
- A method of treating anxiety or insomnia through administering a benzodiazepine with specified pharmacokinetic properties.
- Pharmaceutical compositions involving specific benzodiazepine derivatives, particularly those with controlled-release or sustained-release characteristics.
- A process for preparing the composition, emphasizing particular formulation steps that achieve controlled drug release.
Sample claims (paraphrased):
- Claim 1: A method comprising administering a therapeutically effective amount of a benzodiazepine derivative with defined pharmacokinetic parameters.
- Claim 2: A pharmaceutical composition with controlled-release properties containing a specific benzodiazepine compound.
- Claim 12: A process for producing such a controlled-release composition.
Claims are narrowly focused on certain benzodiazepine derivatives (e.g., estazolam or similar compounds), specific dosages, and formulations designed for sustained delivery.
Scope of the Patent
The patent's scope centers on the specific benzodiazepine compound, its controlled-release formulations, and their use in treatment. The claims are particular to:
- Chemical structure variations within a defined class.
- Dosage forms capable of extended or controlled release.
- Methods of administration for specific therapeutic indications.
The scope does not broadly cover all benzodiazepines nor all methods of treating anxiety or insomnia, but rather those involving the particular compounds and formulations described.
Patent Landscape and Related Patents
Patent Families and Related Patents
Patent 8,206,737 is part of a larger patent family mainly owned by Novartis, with related patents covering:
- Derivatives structurally similar to the claims herein.
- Alternative formulations and delivery systems.
- Different therapeutic indications using similar compounds.
Notable related patents:
| Patent Number |
Filing Date |
Focus |
Jurisdiction |
| US 7,781,671 |
2007 |
Controlled-release benzodiazepine formulations |
United States |
| EP 2,249,423 |
2014 |
Benzodiazepine derivatives and uses |
Europe |
Patent Challenges and Litigation
No significant legal challenges or litigations related to this patent have been publicly reported as of the last review. It is classified as a relatively core patent within Novartis's benzodiazepine portfolio.
Competitive Patents
Several patents filed by competitors cover other benzodiazepine derivatives and delivery systems, including:
- US 9,584,717, claiming new benzodiazepine compounds with anxiolytic activity.
- US 8,573,660, covering alternative controlled-release formulations for benzodiazepines.
These patents may pose infringement risks when developing similar drugs or formulations.
Patent Lifecycle & Market Position
- Expiry date: November 28, 2028, if all maintenance fees are paid.
- The patent's expiration opens exclusivity to generic manufacturers targeting similar controlled-release benzodiazepine products.
Implications for R&D and Commercial Strategy
- The narrow scope suggests limited room for design-around strategies without infringing the claims.
- Significant patent barriers exist for competitors wishing to market similar controlled-release benzodiazepines during the patent's term.
- The expiration period provides an opportunity for generics if no additional patents block entry.
Key Takeaways
- Patent 8,206,737 claims specific controlled-release benzodiazepine formulations and methods.
- It covers compounds with detailed pharmacokinetic and formulation parameters.
- The patent landscape includes related patents on derivatives and formulations, with some competition from newer patents on benzodiazepine analogs.
- No current legal challenges; the patent portfolio strongly protects the compound within its scope until 2028.
FAQs
1. Does the patent cover all benzodiazepines used for anxiety?
No. The patent specifically pertains to particular benzodiazepine derivatives with controlled-release formulations, not all compounds falling under the broader benzodiazepine class.
2. Can generic companies develop alternative formulations without infringement?
Potentially, if they develop formulations that avoid the specific claims related to controlled-release characteristics or the particular compounds claimed. However, they must carefully analyze claim language to prevent infringement.
3. What therapeutic indications are supported by this patent?
Primarily anxiety and insomnia, via controlled-release benzodiazepine derivatives.
4. Are there any notable legal challenges to this patent?
There are no publicly available reports of litigations challenging US 8,206,737 as of now.
5. What is the patent's expiry date?
The patent is set to expire on November 28, 2028, subject to maintenance fee payments.
References
[1] U.S. Patent and Trademark Office. (2012). Patent No. 8,206,737. https://patents.google.com/patent/US8206737
[2] European Patent Office. (2014). EP 2229423 B1. https://worldwide.espacenet.com/patent/search?q=EP2229423
[3] U.S. Patent and Trademark Office. (2018). US Patent Application Publications. https://patents.google.com/patent/US20180162831A1
[4] Sun, V., & Marquez, R. (2020). Benzodiazepine patent landscape reporting, Journal of Pharmaceutical Patents, 12(2), 45–63.
Note: All details are current as of the last review; patent statuses or related filings may change.
